Literature DB >> 6994980

Drug kinetics in childbirth.

R L Nation.   

Abstract

Drugs from a wide range of pharmacological classes are commonly given to women in childbirth, either for a maternal effect or a fetal/neonatal effect. A number of striking physiological and biochemical changes occur during labour and delivery that might alter drug kinetics. The rate of drug absorption from the gastrointestinal tract may be normal in labour provided that narcotic analgesics are not administered concurrently. Altered blood flow characteristics in the extremities could modify drug absorption from intramuscular injection sites. Drug distribution might be altered as a result of the presence of placental-fetal tissues, or as a consequence of changes in, for example, maternal blood volume, concentrations of proteins and other endogenous compounds, cardiac output or tissue perfusion. Although data are scanty on the status of the physiological determinants of drug clearance, that limited information available suggests that drug clearance could be altered in childbirth. The possibility of a placental and/or fetal contribution should not be overlooked when considering the clearance of drugs administered during labour and delivery. Uterine contractions, maternal posture and obstetric medication have been found to affect the extent of some of the physiological changes that occur. Consequently, drug disposition could be modified by these factors. All of the drugs given to women in childbirth are capable of crossing the placenta to some degree. This is a disadvantage in those cases where drugs are given for a maternal effect and may result in neonatal sequelae. The fetal exposure to, and neonatal burden at delivery of, drugs administered during labour and delivery may be influenced by many factors, including maternal posture, mode of drug administration, the drug administraton to delivery interval, fetal pH, and whether intravenous bolus drug administration coincides with the contraction or relaxation phase of uterine activity. Protracted elimination by the neonate may occur for those drugs acquired in utero. Realisation of this is of considerable importance in the clinical management of the newborn.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6994980     DOI: 10.2165/00003088-198005040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  142 in total

1.  Effects of pH on protein binding of lidocaine.

Authors:  R G Burney; C A DiFazio; J A Foster
Journal:  Anesth Analg       Date:  1978 Jul-Aug       Impact factor: 5.108

2.  Placental transfer of clindamycin and gentamicin in term pregnancy.

Authors:  A J Weinstein; R S Gibbs; M Gallagher
Journal:  Am J Obstet Gynecol       Date:  1976-04-01       Impact factor: 8.661

3.  Placental transfer of lidocaine: effects of fetal acidosis.

Authors:  D Biehl; S M Shnider; G Levinson; K Callender
Journal:  Anesthesiology       Date:  1978-06       Impact factor: 7.892

4.  Letter: Perinatal metabolism of diazepam.

Authors:  J Kanto; R Erkkola; R Sellman
Journal:  Br Med J       Date:  1974-03-30

5.  The effects of diazepm on the fetus.

Authors:  J Scher; D M Hailey; R W Beard
Journal:  J Obstet Gynaecol Br Commonw       Date:  1972-07

6.  Maternal cardiovascular dynamics. 3. Labor and delivery under local and caudal analgesia.

Authors:  K Ueland; J M Hansen
Journal:  Am J Obstet Gynecol       Date:  1969-01-01       Impact factor: 8.661

7.  Antiepileptic drugs: metabolism in pregnancy.

Authors:  M Dam; J Christiansen; O Munck; K I Mygind
Journal:  Clin Pharmacokinet       Date:  1979 Jan-Feb       Impact factor: 6.447

8.  The passage of ampicillin into the liquor amnii and the foetal circulation.

Authors:  J D Williams; D J Felton
Journal:  J Obstet Gynaecol Br Commonw       Date:  1966-08

9.  Disposition of meperidine in pregnancy.

Authors:  D Morgan; G Moore; J Thomas; E Triggs
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

10.  Meperidine and normeperidine levels following meperidine administration during labor. II. Fetus and neonate.

Authors:  B R Kuhnert; P M Kuhnert; A S Tu; D C Lin
Journal:  Am J Obstet Gynecol       Date:  1979-04-15       Impact factor: 8.661

View more
  8 in total

Review 1.  Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.

Authors:  Sílvia M Illamola; Christina Bucci-Rechtweg; Maged M Costantine; Ekaterini Tsilou; Catherine M Sherwin; Anne Zajicek
Journal:  Br J Clin Pharmacol       Date:  2017-10-22       Impact factor: 4.335

2.  A survey of pharmacokinetic data from pregnant women.

Authors:  A J Cummings
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

3.  Disposition of betamethasone in parturient women after intravenous administration.

Authors:  M C Petersen; C B Collier; J J Ashley; W G McBride; R L Nation
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Placental transfer of etozolin and ozolinone during the first half of gestation in man.

Authors:  H Nau; R Steldinger; E Ivan
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women.

Authors:  Anouk E Muller; P Joep Dörr; Johan W Mouton; Joost De Jongh; Paul M Oostvogel; Eric A P Steegers; Rob A Voskuyl; Meindert Danhof
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

Review 6.  Excretion of psychoactive drugs into breast milk. Pharmacokinetic principles and recommendations.

Authors:  G Pons; E Rey; I Matheson
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

7.  Comparison of the placental transfer of thiopental and diazepam in caesarean section.

Authors:  O M Bakke; K Haram; T Lygre; G Wallem
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Relationship between the transplacental gradients of bupivacaine and alpha 1-acid glycoprotein.

Authors:  M C Petersen; R G Moore; R L Nation; W McMeniman
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.